Welcome to our dedicated page for TLWR news (Ticker: TLWR), a resource for investors and traders seeking the latest updates and insights on TLWR stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TLWR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TLWR's position in the market.
Talawar Therapeutics and JATT II (Nasdaq: JATT) signed a definitive business combination to create a Nasdaq-listed biotech, expected to trade as TLWR in 2H 2026. The deal includes a $225 million oversubscribed PIPE at $10 per share and $60 million in JATT II trust, for $285 million gross proceeds assuming no redemptions. Available cash at closing is anticipated to fund lead bispecific antibody TALA-125 for atopic dermatitis through a Phase 2b proof-of-concept data readout in 2H 2028. TALA-125 is expected to enter the clinic in 1Q 2027, with interim Phase 1 data in 4Q 2027. Talawar also advances discovery programs TALA-307 and TALA-711 in additional immunology indications.